SCHEMBL3598705

SCHEMBL3598705

COc1c(C)c(S(=O)(=O)c2cccc(N)c2)n2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
F2 P00734 1/20 0.40
PRSS1 P07477 1/20 0.40
PRSS2 P07478 1/20 0.40
PRSS3 P35030 1/20 0.40
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
PKM P14618 2/20 0.37
ALDH1A1 P00352 4/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MET P08581 1/20 0.37
CYP19A1 P11511 1/20 0.36
HTR6 P50406 4/20 0.36
POLB P06746 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603667 0.86 HTR6 (0.41) LMNAF2PRSS1PRSS2PRSS3
SCHEMBL3600190 0.81 KMT2A (0.50) LMNAF2PRSS1PRSS2PRSS3
SCHEMBL3597788 0.76 FBP1 (0.39) LMNAF2PRSS1PRSS2PRSS3
SCHEMBL16396172 0.67 LMNA (0.69) LMNAF2PRSS1PRSS2PRSS3
SCHEMBL30544199 0.66 LMNA (1.00) LMNAF2PRSS1PRSS2PRSS3
SCHEMBL5561963 0.66 LMNA (1.00) LMNAF2PRSS1PRSS2PRSS3
SCHEMBL29635012 0.66 LMNA (1.00) LMNAF2PRSS1PRSS2PRSS3
SCHEMBL34546 0.66 LMNA (1.00) LMNAF2PRSS1PRSS2PRSS3
SCHEMBL487472 0.65 LMNA (0.87) LMNAF2PRSS1PRSS2PRSS3
Benzene SCHEMBL27752989 0.65 LMNA (0.95) LMNAF2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803811-B2 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2010-09-28 US claimed
US-20090023770-A1 Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them SANOFI-AVENTIS (FR) 2009-01-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023770-A1 Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them FGF2, FGF1, FGFR1 LMNA 3251/4885F2 502/4885PRSS1 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.